CurrentUnitedHealthcarePolicy N/A

Ruconest (C1 esterase inhibitor [recombinant]) prior authorization and medical necessity

Criteria and authorization requirements for initial and reauthorization coverage of Ruconest for treatment of acute hereditary angioedema (HAE) attacks for UnitedHealthcare members; applies to providers prescribing and seeking prior authorization.

Policy Summary

PayerUnitedHealthcare

PolicyRuconest (C1 esterase inhibitor [recombinant]) prior authorization and medical necessity

Policy CodePolicy N/A

Change TypeRoutine review — no material changes

Effective DateJul 1, 2025

Next Review DateApr 1, 2025

Key ActionObtain prior authorization and provide diagnostic documentation (C1‑INH antigenic or functional level or confirmatory genetic testing) and ensure prescription is from an immunologist or allergist.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

acute HAE attacksindication

12 monthsauthorization duration

specialty requiredprescriber specialty limited

automated approvalsadditional clinical program allowances

Coverage Criteria for Ruconest

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy

Covered when ALL of the following are met:

Initial Authorization

Diagnostic confirmation - Type I or II HAE: C1-INH antigenic level below the lower limit of normal OR C1-INH functional level below the lower limit of normal
per laboratory standard
Diagnostic confirmation - HAE with normal C1-INH: Either confirmed pathogenic variant(s) in one of the specified genes (factor XII, angiopoietin-1, plasminogen, kininogen-1, myoferlin, HS3ST6) OR recurring angioedema attacks refractory to high-dose antihistamines (with or without family history)
includes de-novo or familial cases

Treatment use and restrictions: Prescribed for the acute treatment of HAE attacks AND not used in combination with other products indicated for the acute treatment of HAE attacks (e.g., Berinert, Firazyr)

Prescriber specialty: Prescription must be by an immunologist or allergist

Authorization will be issued for 12 months

Reauthorization

Reauthorization covered when ALL of the following are met:

Clinical response: Documentation of positive clinical response to Ruconest therapy

Indication and restrictions: Prescribed for the acute treatment of HAE attacks AND not used in combination with other products indicated for the acute treatment of HAE attacks (e.g., Berinert, Firazyr)

Authorization will be issued for 12 months

Prescriber specialty: Prescription must be by an immunologist or allergist

Effectiveness of Ruconest for laryngeal attacks in hereditary angioedema has not been established. This policy therefore notes that evidence of benefit for laryngeal HAE presentations is lacking and such presentations should be considered when evaluating medical necessity and expected clinical response.

Provider Requirements and Actions

Prior Authorization

Prior Authorization Required

Prior authorization required. Initial approval will be issued when the listed diagnostic and prescribing criteria are met. Authorization of therapy will be issued for 12 months.

Initial authorization criteria must document HAE diagnosis by C1-INH antigenic or functional level OR confirmed pathogenic variant in HAE-related genes.
Prescribed for the acute treatment of HAE attacks.
Prescribing provider specialty: Immunologist or Allergist.

Documentation Required

Diagnostic Documentation Required

Documentation must include diagnostic laboratory confirmation of hereditary angioedema (HAE) by one of the following: C1‑INH antigenic level below the laboratory lower limit of normal, C1‑INH functional level below the laboratory lower limit of normal, or confirmed pathogenic variant(s) in HAE‑related genes (e.g., factor XII, angiopoietin‑1, plasminogen, kininogen‑1, myoferlin, HS3ST6).

If C1‑INH levels are normal, provide genetic test results confirming a pathogenic variant associated with HAE.
Include clinical history supporting recurrent angioedema attacks refractory to high‑dose antihistamines when relevant.

Denial Risk

Combination Therapy Restriction / Denial Risk

Not to be used in combination with other acute HAE attack products. Lack of documentation confirming HAE diagnosis by C1‑INH antigenic/functional level or appropriate genetic testing may result in denial.

Combination therapy restriction: Do not administer with other products indicated for acute HAE attacks (e.g., Berinert, Firazyr).
Denial risk: Absence of required diagnostic laboratory or genetic documentation may lead to claim denial.

Definitions

Type I/II HAE definition — C1-INH deficiency/dysfunction documented by low antigenic or functional levels.

DefinitionHereditary angioedema (Type I or II) caused by C1 inhibitor (C1‑INH) deficiency or dysfunction.

Diagnostic criteriaC1‑INH antigenic level below the lower limit of normal (per laboratory standard).

Alternate diagnostic criterionC1‑INH functional level below the lower limit of normal (per laboratory standard).

Laboratory standardMeasurements interpreted against laboratory‑specific lower limits of normal as documented in source labs.

HAE with normal C1-INH — confirmed by specified genetic variants or recurrent refractory angioedema.

DefinitionHereditary angioedema with normal C1‑INH levels (HAE with normal C1‑INH).

Genetic confirmationConfirmed presence of pathogenic variant(s) in one of: factor XII, angiopoietin‑1, plasminogen, kininogen‑1, myoferlin, or HS3ST6.

Clinical confirmation — de novoRecurrent angioedema attacks refractory to high‑dose antihistamines with unknown background (de‑novo, no family history).

Clinical confirmation — familialRecurrent angioedema attacks refractory to high‑dose antihistamines with confirmed family history of angioedema.